ALLERGIC ASTHMA THERAPEUTICS MARKET ANALYSIS

Market News

Global Allergic Asthma Therapeutics Market- Key Developments

In March 2022, the U.S FDA, announced the approval of general drug-device combination product approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and (Chronic obstructive pulmonary disease) COPD is another step forward in our commitment to bring generic copies of complex drugs to the market, which e improve quality of life and help reduce the cost of treatment.

On April 18 2023, GSK plc., a global biopharma company and BELLUS Health Inc., a drug development company, announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company, working to better the lives of patients suffering from refractory chronic cough (RCC) for US$ 14.75 per share of common stock in cash representing an approximate total equity value of US$ 2 billion. The acquisition provides GSK, plc., access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.

In December 2021, AstraZeneca, a global biopharmaceutical company developing innovative medicines and Amgen, Inc., a multinational biopharmaceutical company Tezspire (tezepelumab-ekko) has been approved in the U.S. for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire was approved following a Priority Review by the U.S. Food and Drug Administration (FDA) and based on results from the PATHFINDER clinical trial programme. The application included results from the pivotal NAVIGATOR Phase III trial in which Tezspire demonstrated superiority across every primary and key secondary endpoint in patients with severe asthma, compared to placebo, when added to standard therapy.

In February 2021, CHIESI Farmaceutici S.p.A., an international research-focused healthcare group, announced that the European Commission has granted the marketing authorisation for Trimbow (beclometasone/formoterol/glycopyrronium), an extrafine formulation triple fixed combination therapy in a single inhaler, as a maintenance treatment for adult asthma patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and medium dose of inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous year